Pharming Group (NASDAQ:PHAR - Free Report) - Stock analysts at HC Wainwright reduced their FY2025 earnings estimates for Pharming Group in a research report issued on Tuesday, October 15th. HC Wainwright analyst J. Pantginis now forecasts that the company will post earnings per share of $0.60 for the year, down from their previous forecast of $0.65. HC Wainwright has a "Buy" rating and a $37.00 price objective on the stock. The consensus estimate for Pharming Group's current full-year earnings is ($0.15) per share.
Pharming Group Stock Down 0.2 %
Shares of PHAR stock traded down $0.02 during trading hours on Wednesday, hitting $8.68. 1,535 shares of the company's stock traded hands, compared to its average volume of 4,861. The stock's fifty day simple moving average is $7.89 and its two-hundred day simple moving average is $8.64. Pharming Group has a 12-month low of $6.65 and a 12-month high of $13.20. The stock has a market cap of $584.55 million, a price-to-earnings ratio of -54.38 and a beta of 0.15. The company has a quick ratio of 2.65, a current ratio of 3.39 and a debt-to-equity ratio of 0.40.
Pharming Group (NASDAQ:PHAR - Get Free Report) last issued its quarterly earnings data on Thursday, August 1st. The company reported ($0.01) EPS for the quarter. Pharming Group had a negative return on equity of 5.69% and a negative net margin of 4.65%. The company had revenue of $74.09 million during the quarter, compared to analysts' expectations of $71.95 million. During the same quarter last year, the business earned $0.02 earnings per share.
Hedge Funds Weigh In On Pharming Group
A hedge fund recently raised its stake in Pharming Group stock. Silverberg Bernstein Capital Management LLC grew its holdings in shares of Pharming Group (NASDAQ:PHAR - Free Report) by 32.3% in the 2nd quarter, according to its most recent disclosure with the SEC. The fund owned 23,435 shares of the company's stock after purchasing an additional 5,725 shares during the period. Silverberg Bernstein Capital Management LLC's holdings in Pharming Group were worth $196,000 as of its most recent SEC filing. Institutional investors and hedge funds own 0.03% of the company's stock.
About Pharming Group
(
Get Free Report)
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.
Featured Articles
Before you consider Pharming Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pharming Group wasn't on the list.
While Pharming Group currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
